Floatz logo

Recombinant Fowlpox-Tricom Vaccine

Unspecified Adult Solid Tumor, Protocol Specific

National Cancer Institute (NCI)vaccinePhase 1Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Unspecified Adult Solid Tumor, Protocol Specific cohort.

Asset / SponsorPhaseRating
Amifostine
M.D. Anderson Cancer Center
Phase 4BBB
NEPENTHE
M.D. Anderson Cancer Center
Phase 4BBB
DEXAMETHASONE
Alliance for Clinical Trials in Oncology
Phase 3BBB
ETOPOSIDE
University of California, Davis
Phase 2/3BBB
FILGRASTIM
National Institutes of Health Clinical Center (CC)
Phase 3BBB

View all 50 →

Same molecule, other indications

Recombinant Fowlpox-Tricom Vaccine is also rated in:

prostate cancerDormant
C
Indicative ·
36 / 100
View asset →
melanomaDormant
C
Indicative ·
36 / 100
View asset →
metastatic melanomaDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →